Yeah, I agree its not a bad thing, but its always hard as a new...

Yeah, I agree its not a bad thing, but its always hard as a new company. With government contracts, you usually have 3-5 year supply contracts in place and the only way we will be getting into that market is OEM device sales. That's also If a company uses a supplier and doesn't make em themselves. New product launches will be a much harder and longer process. But now there is pushes to start using more Australian companies to use your products, so it does potentially open up avenues long term.

I am still waiting on an opportunity to buy back in and my order nearly got filled at 0.29 before the announcement. but after assessing the announcement, I believe we will still fall back to the low 0.3 range, so ill pick some up then.

Hey, the revenue alone from this NG Biotech deal could still send the price of this stock skyrocketing, but it's all higly speculative until we see the sales numbers.